XORTX discloses US$240,000 finder’s fees tied to Vectus renal program acquisition after omission
Vectus Biosystems Seeks ASX Quotation for 7.9 Million New Shares
Vectus Biosystems Grants 981,000 Unquoted Options Under Employee Scheme
Vection Technologies Seeks ASX Quotation for 66.9 Million New Shares
Voolt SA - Raport roczny
BioVersys Cleared By FDA To Begin Phase 3 Trial Of BV100 For Drug-Resistant Hospital Pneumonia